Cargando…

Negative effects of iodine-based contrast agent on renal function in patients with moderate reduced renal function hospitalized for COVID-19

BACKGROUND: Kidney disease and renal failure are associated with hospital deaths in patients with COVID − 19. We aimed to test if contrast enhancement affects short-term renal function in hospitalized COVID − 19 patients. METHODS: Plasma creatinine (P-creatinine) was measured on the day of computed...

Descripción completa

Detalles Bibliográficos
Autores principales: Kistner, Anna, Tamm, Chen, Svensson, Ann Mari, Beckman, Mats O., Strand, Fredrik, Sköld, Magnus, Nyrén, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8407403/
https://www.ncbi.nlm.nih.gov/pubmed/34465289
http://dx.doi.org/10.1186/s12882-021-02469-w
_version_ 1783746625544388608
author Kistner, Anna
Tamm, Chen
Svensson, Ann Mari
Beckman, Mats O.
Strand, Fredrik
Sköld, Magnus
Nyrén, Sven
author_facet Kistner, Anna
Tamm, Chen
Svensson, Ann Mari
Beckman, Mats O.
Strand, Fredrik
Sköld, Magnus
Nyrén, Sven
author_sort Kistner, Anna
collection PubMed
description BACKGROUND: Kidney disease and renal failure are associated with hospital deaths in patients with COVID − 19. We aimed to test if contrast enhancement affects short-term renal function in hospitalized COVID − 19 patients. METHODS: Plasma creatinine (P-creatinine) was measured on the day of computed tomography (CT) and 24 h, 48 h, and 4–10 days after CT. Contrast-enhanced (n = 142) and unenhanced (n = 24) groups were subdivided, based on estimated glomerular filtration rates (eGFR), > 60 and ≤ 60 ml/min/1.73 m(2). Contrast-induced acute renal failure (CI-AKI) was defined as ≥27 μmol/L increase or a > 50% rise in P-creatinine from CT or initiation of renal replacement therapy during follow-up. Patients with renal replacement therapy were studied separately. We evaluated factors associated with a > 50% rise in P-creatinine at 48 h and at 4–10 days after contrast-enhanced CT. RESULTS: Median P-creatinine at 24–48 h and days 4–10 post-CT in patients with eGFR> 60 and eGFR≥30–60 in contrast-enhanced and unenhanced groups did not differ from basal values. CI-AKI was observed at 48 h and at 4–10 days post contrast administration in 24 and 36% (n = 5/14) of patients with eGFR≥30–60. Corresponding figures in the eGFR> 60 contrast-enhanced CT group were 5 and 5% respectively, (p < 0.037 and p < 0.001, Pearson χ(2) test). In the former group, four of the five patients died within 30 days. Odds ratio analysis showed that an eGFR≥30–60 and 30-day mortality were associated with CK-AKI both at 48 h and 4–10 days after contrast-enhanced CT. CONCLUSION: Patients with COVID − 19 and eGFR≥30–60 had a high frequency of CK-AKI at 48 h and at 4–10 days after contrast administration, which was associated with increased 30-day mortality. For patients with eGFR≥30–60, we recommend strict indications are practiced for contrast-enhanced CT. Contrast-enhanced CT had a modest effect in patients with eGFR> 60.
format Online
Article
Text
id pubmed-8407403
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84074032021-09-01 Negative effects of iodine-based contrast agent on renal function in patients with moderate reduced renal function hospitalized for COVID-19 Kistner, Anna Tamm, Chen Svensson, Ann Mari Beckman, Mats O. Strand, Fredrik Sköld, Magnus Nyrén, Sven BMC Nephrol Research BACKGROUND: Kidney disease and renal failure are associated with hospital deaths in patients with COVID − 19. We aimed to test if contrast enhancement affects short-term renal function in hospitalized COVID − 19 patients. METHODS: Plasma creatinine (P-creatinine) was measured on the day of computed tomography (CT) and 24 h, 48 h, and 4–10 days after CT. Contrast-enhanced (n = 142) and unenhanced (n = 24) groups were subdivided, based on estimated glomerular filtration rates (eGFR), > 60 and ≤ 60 ml/min/1.73 m(2). Contrast-induced acute renal failure (CI-AKI) was defined as ≥27 μmol/L increase or a > 50% rise in P-creatinine from CT or initiation of renal replacement therapy during follow-up. Patients with renal replacement therapy were studied separately. We evaluated factors associated with a > 50% rise in P-creatinine at 48 h and at 4–10 days after contrast-enhanced CT. RESULTS: Median P-creatinine at 24–48 h and days 4–10 post-CT in patients with eGFR> 60 and eGFR≥30–60 in contrast-enhanced and unenhanced groups did not differ from basal values. CI-AKI was observed at 48 h and at 4–10 days post contrast administration in 24 and 36% (n = 5/14) of patients with eGFR≥30–60. Corresponding figures in the eGFR> 60 contrast-enhanced CT group were 5 and 5% respectively, (p < 0.037 and p < 0.001, Pearson χ(2) test). In the former group, four of the five patients died within 30 days. Odds ratio analysis showed that an eGFR≥30–60 and 30-day mortality were associated with CK-AKI both at 48 h and 4–10 days after contrast-enhanced CT. CONCLUSION: Patients with COVID − 19 and eGFR≥30–60 had a high frequency of CK-AKI at 48 h and at 4–10 days after contrast administration, which was associated with increased 30-day mortality. For patients with eGFR≥30–60, we recommend strict indications are practiced for contrast-enhanced CT. Contrast-enhanced CT had a modest effect in patients with eGFR> 60. BioMed Central 2021-08-31 /pmc/articles/PMC8407403/ /pubmed/34465289 http://dx.doi.org/10.1186/s12882-021-02469-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kistner, Anna
Tamm, Chen
Svensson, Ann Mari
Beckman, Mats O.
Strand, Fredrik
Sköld, Magnus
Nyrén, Sven
Negative effects of iodine-based contrast agent on renal function in patients with moderate reduced renal function hospitalized for COVID-19
title Negative effects of iodine-based contrast agent on renal function in patients with moderate reduced renal function hospitalized for COVID-19
title_full Negative effects of iodine-based contrast agent on renal function in patients with moderate reduced renal function hospitalized for COVID-19
title_fullStr Negative effects of iodine-based contrast agent on renal function in patients with moderate reduced renal function hospitalized for COVID-19
title_full_unstemmed Negative effects of iodine-based contrast agent on renal function in patients with moderate reduced renal function hospitalized for COVID-19
title_short Negative effects of iodine-based contrast agent on renal function in patients with moderate reduced renal function hospitalized for COVID-19
title_sort negative effects of iodine-based contrast agent on renal function in patients with moderate reduced renal function hospitalized for covid-19
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8407403/
https://www.ncbi.nlm.nih.gov/pubmed/34465289
http://dx.doi.org/10.1186/s12882-021-02469-w
work_keys_str_mv AT kistneranna negativeeffectsofiodinebasedcontrastagentonrenalfunctioninpatientswithmoderatereducedrenalfunctionhospitalizedforcovid19
AT tammchen negativeeffectsofiodinebasedcontrastagentonrenalfunctioninpatientswithmoderatereducedrenalfunctionhospitalizedforcovid19
AT svenssonannmari negativeeffectsofiodinebasedcontrastagentonrenalfunctioninpatientswithmoderatereducedrenalfunctionhospitalizedforcovid19
AT beckmanmatso negativeeffectsofiodinebasedcontrastagentonrenalfunctioninpatientswithmoderatereducedrenalfunctionhospitalizedforcovid19
AT strandfredrik negativeeffectsofiodinebasedcontrastagentonrenalfunctioninpatientswithmoderatereducedrenalfunctionhospitalizedforcovid19
AT skoldmagnus negativeeffectsofiodinebasedcontrastagentonrenalfunctioninpatientswithmoderatereducedrenalfunctionhospitalizedforcovid19
AT nyrensven negativeeffectsofiodinebasedcontrastagentonrenalfunctioninpatientswithmoderatereducedrenalfunctionhospitalizedforcovid19